Table 10. Sensitivity of MRI to detect any-grade cancer or csPCa using location matching.
| Sensitivity | Reader 1 | Reader 2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CDWI | DL1 | DL2 | DL3 | CDWI | DL1 | DL2 | DL3 | ||
| Any prostate cancer, sensitivity (%) | 71.4 | 67.1 | 75.7 | 70.0 | 64.3 | 72.9 | 72.9 | 68.6 | |
| csPCa, sensitivity (%) | 80.4 | 78.4 | 86.3 | 82.4 | 78.4 | 84.3 | 86.3 | 84.3 | |
| 95% CI | 66.9–90.2 | 64.7–88.7 | 73.7–94.3 | 69.1–91.6 | 66.9–90.2 | 64.7–88.7 | 73.7–94.3 | 69.1–91.6 | |
MRI, magnetic resonance imaging; csPCa, clinically significant prostate cancer (Gleason score ≥3+4); CDWI, conventional diffusion weighted image; DL1, DWI with iPAT2 using DLR; DL2, DWI with iPAT3 using DLR; DL3, DWI with iPAT3 and reduced averages per b-value using DLR; CI, confidence interval; DWI, diffusion weighted imaging; DLR, deep learning reconstruction; iPAT2, acceleration factor 2; iPAT3, acceleration factor 3.